William Marth of Israel's Teva, the world's biggest generics firm, insists that biosimilars are a “natural segue” for his company and predicts that sales will reach $800m by 2015. Cipla, an Indian generics maker, and China's Desano Pharma are also getting into the biosimilars business.
基于1个网页-相关网页
应用推荐